Strides gets USFDA nod for Oseltamivir Phosphate for Oral Suspension

18 Jan 2022 , 12:56 PM

Strides Pharma Science Limited (Strides) announced its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Oseltamivir Phosphate for Oral Suspension,6 mg/mL from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Tamiflu for Oral Suspension, 6 mg/mL, of Hoffmann-La Roche, Inc.

According to IQVIA MAT November 2020 data, the US market for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL was approximately ~US$ 132 Mn. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.  

The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval.

The stock is currently trading at Rs440.65 down by Rs4.35 or 0.98% from its previous closing of Rs445 on the BSE. The scrip opened at Rs452 and has touched a high and low of Rs466.60 and Rs438.90 respectively.